Professor Sara Hurvitz (David Geffen School of Medicine at UCLA, Los Angeles, CA, USA) discusses her presentation at the San Antonio Breast Cancer Symposium 2021 on the aims, efficacy and safety findings of the coopERA study.
Questions
1. What is giredestrant, and what is the rationale for its use in HR+, HER2− early breast cancer? 00:14-01:14
2. Could you tell us a little about the coopERA clinical study and its findings? 01:15-04:30
Speaker Disclosure: Sara Hurvitz has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the San Antonio Breast Cancer Symposium 2021
